Compound Guide
BPC-157 Research — Body Protective Compound 157, Tissue Repair & Angiogenesis
Editorial Standards
Avera Refined Wellness holds its research journal content to a standard requiring specific research claims to reference published, peer-reviewed sources — not general assertions. We are in the process of auditing and updating existing journal content to consistently meet this standard.
BPC-157 research: pentadecapeptide studied for tissue repair and angiogenesis. 2026 Int J Mol Sci review (PMID 41898733). 30+ years preclinical data.
All products are supplied strictly for in-vitro laboratory research use only by qualified professionals. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
BPC-157 is a stable synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of body protection compound isolated from human gastric juice. Studied continuously since the early 1990s primarily through Croatian and international academic groups, it has one of the larger preclinical literature bases among research peptides.
Primary Mechanisms
Angiogenesis. BPC-157 upregulates VEGF through the VEGFR2–PI3K–Akt–eNOS axis and a parallel VEGF-independent Src–caveolin-1–eNOS pathway, both converging on nitric oxide production. It also induces EGR-1 and its corepressor NAB2, forming a regulatory feedback loop governing angiogenic gene transcription amplitude.
Tendon fibroblast biology. Chang CH et al. (J Appl Physiol, 2011, PMID: 21030672) showed BPC-157 significantly accelerated tendon explant outgrowth, increased fibroblast survival under oxidative stress, and increased migration via FAK-paxillin phosphorylation. A separate study confirmed 2.29-fold upregulation of growth hormone receptor expression in tendon fibroblasts (PMC6271067).
Nitric oxide modulation. Bidirectional modulation of the NO system — counteracting both deficiency and excess — a homeostatic mechanism documented consistently across the BPC-157 literature.
Anti-inflammatory signaling. Reduces TNF-α, IL-1β, and IL-6; upregulates HO-1 and heat shock proteins.
GI cytoprotection. Among the best-replicated findings across models of colitis, gastric ulcer, NSAID damage, and intestinal anastomosis.
Systematic Reviews (2025–2026)
A 2025 systematic review (Orthopaedic J Sports Med, Vasireddi et al.) analyzed 544 articles from 1993–2024 including 35 preclinical studies. It found improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone. The single human study — intraarticular injection for knee pain — found 7 of 12 patients reported sustained relief beyond six months.
A 2026 review (Yuan C et al., Int J Mol Sci 27(6), PMID: 41898733) provides the most comprehensive current mechanistic synthesis. It confirms favorable preclinical safety data while noting large controlled human trials have not been completed.
Key References
- Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair. Int J Mol Sci. 2026;27(6). PMID: 41898733.
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic J Sports Med. 2025.
- Brcic L, et al. Modulatory effect of BPC 157 on angiogenesis in muscle and tendon healing. PMID: 20388964.
- Chang CH, et al. BPC 157 on tendon healing: outgrowth, survival, and migration. J Appl Physiol. 2011. PMID: 21030672.
- Sikiric P, et al. BPC 157 Therapy: Angiogenesis and Nitric Oxide. Pharmaceuticals. 2025. PMC12567428.
For educational and research reference only. BPC-157 is supplied for in-vitro laboratory research use only. Not for human consumption.
Research Disclaimer: All content published in the Avera Research Journal is provided for informational and scientific discussion purposes only. It does not constitute medical advice, treatment guidance, or a recommendation for human use of any compound. All Avera products are supplied exclusively for in-vitro laboratory research by qualified professionals. Not FDA-evaluated. Not for human consumption.
This article is for informational and research purposes only. All compounds referenced are sold strictly for in-vitro laboratory research use and are not intended for human consumption, veterinary use, or clinical/diagnostic procedures. These statements have not been evaluated by the FDA. Avera Refined Wellness is a subsidiary of RDS 412 LLC.
Related Research